

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
MEMORANDUM OF COOPERATION**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 7 July 2026 (after trading hours), Shenzhen Zhong Ji Health Science Co., Ltd.* (深圳市中基健康科學有限公司) (“**Zhong Ji Health**”), a wholly-owned subsidiary of the Company, entered into a memorandum of cooperation (the “**Memorandum**”) with Shenzhen Zhongtou Huijin Fund Management Co., Ltd.* (深圳中投匯金基金管理有限公司) (“**Shenzhen Zhongtou**”).

PROPOSED ESTABLISHMENT OF A SPECIALIZED M&A FUND FOR THE BIG HEALTH INDUSTRY

Pursuant to the Memorandum, the proposed cooperation will include the joint establishment of a specialized mergers and acquisitions fund for the big health industry (in the form of a limited partnership, hereinafter referred to as the “**M&A Fund**”) by Zhong Ji Health and Shenzhen Zhongtou, with a proposed fund size of RMB1 billion, comprising a first tranche of approximately RMB200 million, a second tranche of approximately RMB300 million and a third tranche of approximately RMB500 million. The specialized M&A Fund for the big health industry will focus on investing in entities operating in the longevity and health sector, including the longevity science industry,

cellular industry, longevity and anti-aging biopharmaceutical industry, and high-end health management. Shenzhen Zhongtou will be responsible for coordinating the fund-raising, investment, and management of the fund.

INFORMATION ON SHENZHEN ZHONGTOU

Shenzhen Zhongtou is a company established in the PRC with limited liability in 2001. Shenzhen Zhongtou is currently a private fund manager registered with the Asset Management Association of China (its current registration number: P1064197). Pursuant to the current PRC laws and regulations, it primarily conducts private fund business, focusing on management and investment businesses related to open-market securities investment, as well as primary and secondary equity investment. Shenzhen Zhongtou has established and participated in the operation of similar industry funds in Beijing, Shanghai, Guangzhou, Jiangsu, Jiangxi, Hainan, Hunan, Hubei, Zhejiang, Xinjiang, and Fujian, including government development funds, industry guidance funds, and M&A funds for listed companies. Currently, the size of funds managed or co-managed by Shenzhen Zhongtou amounts to approximately RMB10 billion, with intended fund commitments totaling approximately RMB120 billion.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, as at the date of this announcement, Shenzhen Zhongtou and its ultimate beneficial owners are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"))).

REASONS FOR AND BENEFITS OF ENTERING INTO THE MEMORANDUM OF COOPERATION

The Company is a company incorporated in Bermuda with limited liability and is an investment holding company which, through its subsidiaries, is principally engaged in the business of longevity science business, money lending, financial and investment advisory, as well as securities, property and investments. Zhong Ji Health is a company established in the PRC with limited liability and is principally engaged in the provision of health longevity management service as well as the production and sales of health longevity products, with a strong focus on the longevity science industry and health sectors such as cellular medicine.

The Board believes that the health and longevity science market has great prospects. The proposed specialized M&A fund for the big health industry is dedicated to becoming a leading M&A fund in the longevity science industry, supporting the development of upstream and downstream enterprises in the longevity science industry. Guided by the principles of industry-finance integration, technology empowerment, compliance and stability, and long-term value, the fund will intensively focus on core sectors such as cellular medicine, biomedicine, medical services, smart healthcare, and wellness and

health industry, aiming to jointly identify high-quality projects with strong growth potential, high barriers to entry and significant social value, thereby promoting the high-quality development of the longevity science industry.

Entering into the Memorandum and the cooperation contemplated thereunder are in line with the Group's longevity science business development strategy and plan and will be beneficial to the Group's future business development. The Board believes that the possible cooperation will further strengthen the Group's presence in the longevity science industry and open up new revenue streams from longevity science for the Company, with a view to bringing more stable and sustained revenue growth to the Group in the long run.

The Memorandum is merely a framework of intent and is not legally binding, and it does not constitute a commitment regarding capital or investment. If any such commitments arise, the Company will make further announcement(s) in accordance with the Listing Rules, where applicable.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
*Chairman, Chief Executive Officer and
Executive Director*

Hong Kong, 7 July 2026

As at the date of this announcement, the Directors are:

Executive Directors:

Mr. Yan Li (*Chairman*)

Mr. Li Xiaoshuang

Non-executive Directors:

Dr. He Yiwu

Mr. Lyu Changshang

Independent Non-executive Directors:

Mr. Huang Jiang

Prof. Huang Cibo

Ms. Wang Huijuan

Ms. Tam Mei Chu

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.